OncoResponse
Sep 13, 2018
Atreca secured $125M; OncoResponse bags $40M; Kodiak Sciences’s IPO; Biodesy contemplates $20M
Atreca secured USD 125 Million when solid tumor trial comes into picture California based company, Atreca has bagged USD 125 million to establish its R&D activities. As the company gears up, the series C round enters, to move its lead solid tumor drug into the clinic. Atreca has set up its credentials through V...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
